A federal jury in Newark, N.J., has found, after a 14-day trial, that three generic drugmakers infringed Pfizer Inc.’s patent on its acid-reflux drug, Protonix.

The jury found on April 23 that Teva Pharmaceuticals USA Inc., Kudco Ireland Ltd. and Sun Pharma Global Inc. infringed on the patent when they filed applications with the Food and Drug Administration to sell generic versions of Protonix.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]